Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02648048 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 15
- Study locations
NCT02648048 is a Phase 1 study of Idiopathic Pulmonary Fibrosis that has completed, run by Hoffmann-La Roche. The registered enrollment target is 21 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (97% lower). The trial reports 15 study locations across 13 states.
The verdict
NCT02648048, a Phase 1 study of Idiopathic Pulmonary Fibrosis, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a single arm, multicenter, open-label, Phase 1b study to evaluate the safety and tolerability of vismodegib in combination with pirfenidone in participants with idiopathic pulmonary fibrosis (IPF) currently being treated with pirfenidone.
Conditions Studied
Interventions
- DRUG Vismodegib
- DRUG Pirfenidone
Study Locations (15)
North Carolina
- Pulmonix LLC - Greensboro
- PMG Research of Wilmington - Wilmington
Washington
- Western Washington Medical Group - Everett
- Swedish Medical Center - Seattle
California
- Scripps Clinic - La Jolla
Florida
- Central Florida Pulmonary Group, PA - Orlando
Illinois
- Suburban Lung Associates - Elk Grove
Indiana
- Medical Consultants, PC ; Pulmonary - Muncie
Kentucky
- University of Louisville - Louisville
Louisiana
- Tulane University Medical School - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-01-15 |
| Est. Completion | 2016-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02648048
The ClinicalTrials.gov registry entry for NCT02648048 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (97% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Vismodegib is the first listed.
NCT02648048 reports 15 study locations spanning 13 distinct geographic areas - top geographies include North Carolina, Washington, California.
Frequently Asked Questions
What is clinical trial NCT02648048 about?
NCT02648048 is a clinical study titled "A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis". This is a single arm, multicenter, open-label, Phase 1b study to evaluate the safety and tolerability of vismodegib in combination with pirfenidone in participants with idiopathic pulmonary fibrosis (IPF) currently being treated with pirfenidone.
What is the current status of trial NCT02648048?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2016-01-15. Estimated completion is 2016-11-30.
What conditions does trial NCT02648048 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT02648048?
The interventions under investigation include: Vismodegib (DRUG), Pirfenidone (DRUG).
Who is sponsoring clinical trial NCT02648048?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02648048 being conducted?
This trial has 15 study locations across California, Florida, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose-Escalation Study of Artesunate Patients With IPF
RECRUITING · Phase 1
-
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
RECRUITING · Phase 1
-
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
RECRUITING · Phase 1
-
NAL ER IPF Respiratory Function and Safety Study
RECRUITING · Phase 1
-
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 1
-
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.